New phase 3 trial data confirm the uniquely high efficacy and good safety profile of the R21/Matrix-M malaria vaccine in African children

Published on February 1, 2024
  • Investigators immunised over 4800 young children in a trial in Burkina Faso, Kenya, Mali and Tanzania and found on average 78% efficacy in the 5–17-month age group over the first year
  • To date 25 million doses manufactured and ready for roll-out by The Serum Institute of India (SII) in the next three to four months

 
Continue reading on website
Other news

Oxford scientists launch ambitious roadmap for a circular carbon plastics economy

January 31, 2024
Researchers from the Oxford Martin Programme on the Future of Plastics, University of Oxford, have outlined ambitious targets to help deliver a sustainable and net zero plastic economy. In a paper published this week in Nature, the authors argue for a rethinking of the technical, economic, and policy paradigms that have entrenched the status-quo, one of rising carbon emissions and uncontrolled pol

New Oxford research hub to propel transformative AI innovations

February 1, 2024
The University of Oxford is to share in a major £80 million investment announced today to develop next-generation artificial intelligence (AI) technologies. The funding, from the Engineering and Physical Sciences Research Council, EPSRC (part of UK Research and Innovation, UKRI), will support nine new AI research hubs in the UK, one of which will be based at the University of Oxford’s Department o